N2OFF's 15min chart shows KDJ Golden Cross, Bullish Marubozu

The 15-minute chart for N2OFF has recently exhibited a bullish trend, as indicated by the KDJ Golden Cross and the appearance of a bullish Marubozu candle at 10:45 on 02/10/2025. This suggests a shift in momentum towards the upside and a potential for further price appreciation. Given the dominance of buyers in the market, it is likely that bullish momentum will continue.

N2OFF, Inc. (NASDAQ: NITO) shareholders have approved the acquisition of SciSparc Ltd.'s (NASDAQ: SPRC) majority-owned subsidiary, MitoCareX Bio Ltd., marking a significant milestone in the deal's progression. The approval, which came during N2OFF's special meeting on September 25, 2025, clears a crucial path for the completion of the acquisition, positioning N2OFF to enter the lucrative oncology market and SciSparc to benefit from potential cancer therapeutic breakthroughs.

Under the agreement announced on February 25, 2025, N2OFF will purchase 6,622 shares of MitoCareX from SciSparc for $700,000 and exchange the remaining outstanding shares with SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri for N2OFF common stock, totaling 40% of N2OFF’s fully diluted capital stock. The sellers will collectively be entitled to 30% of N2OFF’s financing proceeds (capped at $1.6 million) for five years following closing. Additionally, they may receive milestone-based issuances of up to 25% of N2OFF common stock on a fully diluted basis.

N2OFF has committed to financially support MitoCareX’s operations during the first two years post-closing, including an initial $1 million cash investment. The transaction is expected to close in the first half of October 2025, pending satisfaction of remaining conditions.

MitoCareX focuses on developing novel therapies for hard-to-treat cancers by targeting proteins in the mitochondrial SLC25 protein family. The global cancer therapeutics and biotherapeutics market was valued at approximately $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031, according to Coherent Market Insights SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition^[1].

The approval of the acquisition by N2OFF shareholders has had a positive impact on the stock price of N2OFF, with the 15-minute chart exhibiting a bullish trend as indicated by the KDJ Golden Cross and the appearance of a bullish Marubozu candle at 10:45 on 02/10/2025. This suggests a shift in momentum towards the upside and a potential for further price appreciation. Given the dominance of buyers in the market, it is likely that bullish momentum will continue.

The transaction is expected to close in the first half of October 2025, subject to the satisfaction of the remaining closing conditions. Mr. Amitay Weiss, Chairman of the Board of Directors of N2OFF, also serves as the President and a member of the Board of Directors of SciSparc. Additionally, Ms. Liat Sidi, a member of N2OFF’s Board of Directors, also serves as a member of the Board of Directors of SciSparc.